FDA adviser who resigned over Alzheimer’s drug says ‘no good evidence’ it works

One of the FDA advisory panel members who resigned after the agency granted Biogen’s Alzheimer’s drug Accelerated Approval has said “the drug showed no good evidence that it worked.”

Dr. Aaron Kesselheim, professor of medicine at Harvard Medical School faculty member at Brigham Women’s Hospital, spoke to CBS about his stepping down, with a resignation letter blasting the Aduhelm approval as “probably the worst drug approval decision in recent U.S. history.”

The agency’s decision, which was met with mixed reviews marked the first approval of an Alzheimer’s drug in nearly two decades, came after the Peripheral Central Nervous System Drugs Advisory Committee said in November that it was not reasonable to consider clinical benefit of the drug based on one successful study.


“The drug showed no good evidence that it worked because it had important side effects then the FDA is totally switching gears over the last six months approving this drug on the basis of a theory relating to the surrogate marker of amyloid plaques that we as an advisory committee back in November were told to not consider,” Kesselheim told CBS.

According to the FDA, the prescribing information for the drug comes with a warning for temporary swelling in the brain risk of hypersensitivity reactions like angioedema urticaria. Common side effects include amyloid-related imaging abnormalities (ARIA), “headache, fall, diarrhea, confusion/delirium/altered mental status/disorientation.”


In announcing the decision, the FDA noted that the drug was granted “Accelerated Approval,” which allows for drugs targeted at serious conditions that fill an unmet medical need to be approved “based on a surrogate endpoint.” 

“A surrogate endpoint used for accelerated approval is a marker – a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit,” according to the FDA. 

Using surrogate or intermediate clinical endpoints can save “valuable time” in the approval process, the agency noted. However, the company that receives Accelerated Approval will still need to conduct confirmatory trials submit data for review. If the confirmatory trials fail to verify clinical benefit, the FDA may withdraw approval or change label indication of the drug. 


Kesselheim’s resignation was the latest among two other FDA panel members who stepped down after the Accelerated Approval; Dr. David Knopman, Mayo Clinic neurologist Dr. Joel Perlmutter, neurologist of Washington University in St Louis.

“If the FDA allows companies to get drugs approved on the basis of trials that are stopped early, trials that are re-analyzed, that sets a precedent because it tells other companies ‘well I don’t also – I don’t need to run a rigorous trial either,'” Kesselheim said.

“In cases like this where the FDA makes what I think is the wrong decision, I think that we need to understbetter why the decisions were made in this way,” he added.

Source link